Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.

ABSTRACT:

Background

Soft-tissue sarcomas (STS) represent a heterogeneous group of rare tumors including more than 70 different histological subtypes. High throughput molecular analysis (next generation sequencing exome [NGS]) is a unique opportunity to identify driver mutations that can change the usual one-size-fits-all treatment paradigm to a patient-driven therapeutic strategy. The primary objective of the MULTISARC trial is to assess whether NGS can be conducted for a large proportion of metastatic STS participants within a reasonable time, and, secondarily to determine whether a NGS-guided therapeutic strategy improves participant's outcome.

Methods

This is a randomized, multicentre, phase II/III trial inspired by the design of umbrella and biomarker-driven trials. The setting p

SUBMITTER: Italiano A 

PROVIDER: S-EPMC8570026 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature